Abstract:Drug resistance and metastasis are considered to be the major factors leading to tragic prognosis and high rate of mortality in cancer patients. Recent evidences suggest that cancer stem cells (CSCs) possess the essential property of self‐protection from chemotherapy, exhibit the ability to self‐renew and generate cancer cells by asymmetric cell division. Nevertheless, the currently known mechanisms likely explain only the tip of an iceberg about CSC property, acquisition and maintenance. The information from data mining is still limited due to the rarity of CSCs in clinical samples. Ovarian cancer is the most lethal malignancy of the female reproductive system. CSCs in ovarian cancers are considered to acquire the molecular armaments of stem cells, which carry stem cell property and can determine the level of malignant potential of the cancer cells, similar to the findings in other cancer cell types. To overcome the limitation and assess the underlying mechanism, we introduced a set of defined factors (OCT3/4, SOX2, KLF4 and c‐Myc) into human serous ovarian cancer cells, which is one of the most frequently encountered ovarian cancer type in female, through Sendai virus reprogramming, aiming to induce CSC properties in the cancer cells. We then evaluated the CSC properties in the cells. In preliminary data, we observed that the ovarian cancer cells transduced with the four Yamanaka factors showed significantly enhanced pluripotent stem cell properties and drug resistance. We thus named the cells with CSC properties as induced ovarian CSCs (iOCSCs). These iOCSCs could be maintained and expanded up to at least 40 passages. Notably, consistent with the original ovarian cancer cells, iOCSCs could be differentiated into ovarian lineage cells, displaying markers as CA125 and CK‐7, shows that we generate generated iOCSCs with lineage specificity directly from cancer cells. In addition, we also confirmed that the phenotypes of our iOCSCs were reproducible in organoid culture and serial transplantation. The next, we are going to analysis the gene expression, transcriptome and metabolomics in iOCSCs to fully understand CSCs and find out new therapies target. Intriguingly, iOCSCs also acquired the ability to differentiate into cells belonging to the three embryonic germ layers, similar to human iPS cells or ES cells, this finding is probably the dawn of uncovering the stem cell tumorigenecity. It is worth to emphasize again, this great value present approach thus makes it feasible to obtain abundant CSCs to support our understanding and in‐depth research into CSCs and hopefully can help in developing new therapeutic strategies to treat ovarian cancers. Support or Funding Information National Science Council of the Republic of China (NSC) and National Taiwan University Hospital (NTUH), Taiwan

Characteristics of CD133-Sustained Chemoresistant Cancer Stem-Like Cells in Human Ovarian Carcinoma

Identification of cancer stem cell-like cells from human epithelial ovarian carcinoma cell line

Enrichment and Characterization of Ovarian Cancer Stem Cells and Its Potential Clinical Application

Description of the CD 133 + Subpopulation of the Human Ovarian Cancer Cell Line OVCAR 3

Quantitative Analyses of CD133 Expression Facilitate Researches on Tumor Stem Cells.

Expression of Aldehyde Dehydrogenase and Cd133 Defines Ovarian Cancer Stem Cells

The role of CD133 expression in the carcinogenesis and prognosis of patients with lung cancer.

Establishment of induced Ovarian Cancer Stem Cells by Defined Factors

SURF4 Maintains Stem-Like Properties Via BIRC3 in Ovarian Cancer Cells.

Expression of CD133 in endometrial cancer cells and its implications

Isolation and characterization of cancer stem cells from high-grade serous ovarian carcinomas.

Propagating the Ovarian Cancer Stem Cells by Reprogramming the Tumor Cells

Characterization of Primary Ovarian Cancer Cells in Different Culture Systems.

Identification Of A Potential Ovarian High-Grade Serous Cancer Stem Cell Marker And Its Clinicopathological Associations

Effects and Mechanism of RhoC Downregulation in Suppressing Ovarian Cancer Stem Cell Proliferation, Drug Resistance, Invasion and Metastasis

The Expression Status and Prognostic Value of Cancer Stem Cell Biomarker Cd133 in Cutaneous Squamous Cell Carcinoma

Identification and Characterization of Ovarian Cancer-Initiating Cells from Primary Human Tumors

CD133 Expression in Osteosarcoma and Derivation of CD133+ Cells

Identification of Hub Genes and Compounds Controlling Ovarian Cancer Stem Cell Characteristics Via Stemness Indices Analysis.

Ovarian cancer stem cell-specific gene expression profiling and targeted drug prescreening.

Evaluation of characteristics of CD44+CD117+ ovarian cancer stem cells in three dimensional basement membrane extract scaffold versus two dimensional monocultures